Thursday, May 19, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Researchers develop and validate polygenic risk scores for six common diseases

by Medical Finance
in News
Scientists discover a division of labor between genetic switches
9
SHARES
105
VIEWS
Share on FacebookShare on Twitter

A person’s risk of developing diseases such as type 2 diabetes or breast cancer may be influenced by thousands of genetic differences. Looking at a single DNA difference that has a small effect on risk may not be clinically useful, but when hundreds or thousands of these small risks are added up into a single score, often called a polygenic risk score (PRS), they might offer clinically meaningful information about a person’s disease risk. In a new paper published in Nature Medicine, researchers from Brigham and Women’s Hospital, Veterans Affairs (VA) Boston Healthcare System, and Harvard Medical School developed and validated polygenic risk scores for six common diseases. The team also developed informational resources for each disease to help physicians and patients discuss how to incorporate PRS when making medical decisions about screening and prevention.

As a primary care physician myself, I knew that busy physicians were not going to have time to take an entire course on polygenic risk scores. Instead, we wanted to design a lab report and informational resources that succinctly told the doctor and patient what they need to know to make a decision about using a polygenic risk score result in their health care.”


Jason Vassy, MD, MPH, corresponding author, Brigham’s Division of General Internal Medicine & Primary Care, the Brigham’s Precision Population Health at Ariadne Labs and VA Boston

Vassy and colleagues developed the risk scores as part of the Genomic Medicine at VA (GenoVA) Study, a randomized clinical trial of PRS testing among generally healthy adults. The study team developed and validated a laboratory test at the Mass General Brigham Laboratory for Molecular Medicine (LMM) for polygenic risk scores for atrial fibrillation, coronary artery disease, type 2 diabetes, breast cancer, colorectal cancer, and prostate cancer.

The GenoVA Study is currently enrolling patients at the VA Boston Healthcare System, and the investigators reported the results from the first 227 patients, among whom 11 percent were found to have a high polygenic risk score for atrial fibrillation, 7 percent for coronary artery disease, 8 percent for type 2 diabetes, and 6 percent for colorectal cancer. Among men, 15 percent had a high score for prostate cancer, while 13 percent of women had a high score for breast cancer. The GenoVA Study will ultimately enroll more than 1,000 patients and follow them for two years to observe how they and their primary care providers use the polygenic risk scores in clinical care. For example, high-risk patients might choose to undergo screening tests more frequently or take preventive medications that can lower their risk.

The researchers had to address many challenges in implementing a clinical laboratory PRS test. Most importantly, their own observations confirmed a problem that was already known about these scores: they are less accurate in individuals of non-European descent. Most genomic research to date has been conducted in European populations, thus the scores resulting from this research have a weaker ability to predict disease risk among non-European populations. Implementing a polygenic risk score into clinical care that is only accurate for people of European descent would exacerbate existing health disparities. To address this important limitation, the researchers applied additional statistical methods to enable PRS calculation across multiple racial groups.

“Researchers must continue working to increase the diversity of patients participating in genomics research,” said Matthew Lebo, PhD, Chief Laboratory Director at the LMM. “In the meantime, we were heartened to see that we could generate and implement valid genetic scores for patients of diverse backgrounds.”

To date, 52 percent of GenoVA Study enrollees report non-white race and/or Hispanic/Latinx ethnicity.

Another key challenge in bringing polygenic risk score to clinical medicine is that physicians and patients will need support to understand them and use them to make medical decisions. Clinical guidelines do not yet exist to help a physician know whether and how they should treat a patient with a high-risk score differently than an average-risk patient, but the study provides physician- and patient-oriented educational materials to help them incorporate the results. In addition, patients and primary care physicians can seek support from a genetic counselor in the study.

The researchers hope that this first report from the GenoVA Study will be a useful guide for other laboratories and health care systems looking to implement polygenic risk score testing in patient care. “It’s still very early days for precision prevention,” says Vassy, “but we have shown it is feasible to overcome some of the first barriers to bringing polygenic risk scores into the clinic.”

Source:

Brigham and Women’s Hospital

Journal reference:

Hao, L., et al. (2022) Development of a clinical polygenic risk score assay and reporting workflow. Nature Medicine. doi.org/10.1038/s41591-022-01767-6.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Phico Therapeutics establishes Scientific Advisory Board

Phico Therapeutics establishes Scientific Advisory Board

by Medical Finance
May 19, 2022
0

Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics...

Scrapping many Covid testing measures is a grave mistake, says London Medical Laboratory

Win an EVOLVE Manual Pipette Starter Pack from INTEGRA

by Medical Finance
May 19, 2022
0

INTEGRA Biosciences is giving labs a chance to win one of 10 EVOLVE Manual Pipette Starter Packs. EVOLVE pipettes are...

‘Lefty’ protein pumps the brakes during initial stages of embryo differentiation

Using ‘off-the-shelf’ engineered stem cell based therapy for treating glioblastomas post-surgery

by Medical Finance
May 19, 2022
0

Glioblastomas (GBMs) are highly aggressive cancerous tumors of the brain and spinal cord. Brain cancers like GBM are challenging to...

Low Dead Volume Reservir Trays

Low Dead Volume Reservir Trays

by Medical Finance
May 19, 2022
0

Precision manufactured to SBS / SLAS dimensions - Porvair Sciences range of reservoir trays are designed for simple integration with...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Scientists uncover new role of chromatin-modulatory enzyme during cancer development

by Medical Finance
May 19, 2022
0

Researchers at the University of North Carolina at Chapel Hill and the UNC Lineberger Comprehensive Cancer Center have uncovered a...

Olympus discovery center brings advanced microscopy to brain research

Olympus discovery center brings advanced microscopy to brain research

by Medical Finance
May 19, 2022
0

Olympus continues to demonstrate its commitment to advancing bioscience research with the opening of the new Olympus Discovery Center at...

Next Post
Dog brains can detect speech and show different activity patterns to many languages

New drug inhibits growth of the most aggressive meningiomas

Study: BNT162b2 post-exposure-prophylaxis against COVID-19. Image Credit: Rido/Shutterstock

Impact of post-exposure BNT162b2 prophylaxis against SARS-CoV-2 infections

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Accident Injury Information Report Health Rawpixel.com ac5524c1031e4229bc369a9a2a504d1c 620x480
    Roe v. Wade’s (possibly last) anniversary
  • Digital illustration of liver in colour background Liya Graphics 0fff2ea2f60c4e71b4991068b748916f 620x480
    Cellular reprogramming can lead to better liver tissue regeneration in mice
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply